Inspiremd supports cms' final national coverage determination (ncd) expanding coverage of carotid stenting (cas) to include both asymptomatic and standard risk patients

Provides additional treatment options for patients and treating physicians; likely expands cas addressable market potentially accelerates conversion of carotid interventions from surgery (carotid endarterectomy) to minimally invasive cas and tcar procedures inspiremd advancing both cas and tcar stent delivery platforms along u.s. and e.u. regulatory pathways leveraging proven cguard eps stent system tel aviv, israel and miami, oct. 12, 2023 (globe newswire) -- inspiremd, inc. (nasdaq: nspr), developer of the cguard™ embolic prevention stent system (eps) for the prevention of stroke, today announced its support for the centers for medicare and medicaid services (cms) final national coverage determination (ncd) which expands coverage of carotid artery stenting (cas) and transcarotid artery revascularization (tcar) to include both asymptomatic and standard risk patients.
NSPR Ratings Summary
NSPR Quant Ranking